Chemistry, Pharma & Life Sciences

Our attorneys have the benefit of years of patent law experience in the sectors of chemistry, pharma and life sciences. Firstly, we have a strong technical background based on our own scientific education and former experience in research and, secondly, with our vast experience in patent infringement proceedings, we are able to ensure the best possible protection for inventions during patent prosecution. Each technical sector has its own peculiarities and challenges.


In Chemistry, the right approach for defining an invention is often particularly important. For example, where a novel compound can be described with a chemical formula, the patent claims should also comprise other possible structural variants of the compound. If a precise structural definition is not feasible, e.g. for novel polymers, we find alternative solutions to describe and claim such compounds in order to obtain an appropriate scope of protection. Such alternative solutions may be a definition based on specific features of the product itself or features of its production process (product-by-process definition).

In the Pharma sector, our work focuses on the protection of novel pharmaceuticals and developments in the field of galenics for known active pharmaceutical ingredients. Moreover, our experts have many years’ experience in protecting novel medical uses. BARDEHLE PAGENBERG’s attorneys have particular expertise in the field of supplementary protection certificates (SPCs), in both prosecution and infringement proceedings.

Inventions in the field of Life Sciences require a profound understanding and particular expertise in molecular biology, biochemistry, microbiology and immunology, as well as extensive knowledge of dynamic jurisprudence in various countries (Germany, Europe and worldwide, including the US). Biotechnological innovations relating to genes and proteins pose a particular challenge when it comes to drafting patent applications, particularly with respect to the legal requirements of sufficiency of disclosure. Our experts can support you in effectively meeting these requirements.
 

BARDEHLE PAGENBERG
Partnerschaft mbB

Patentanwälte Rechtsanwälte

Prinzregentenplatz 7
81675 Munich
Germany

Phone: +49 89 928 05-0
Fax: +49 89 928 05-444
Email: info(at)bardehle.de

Show route

News

Interested in our latest news on Chemistry, Pharma & Life Sciences? Here we go.

UPC News
Firm News on
UPC News, Munich, Patent Litigation, Chemistry, Pharma & Life Sciences
BARDEHLE PAGENBERG successfully enforces two decisions for 10x Genomics against NanoString, winning one of the first UPC penalty payment decisions

On December 5, 2023, the Unified Patent Court, Local Division Munich, ordered NanoString to pay a…

UPC News
Firm News on
UPC News, Munich, Patent Litigation, Patent Prosecution, Chemistry, Pharma & Life Sciences
AAS/EIs available at Munich Local Division of the UPC

On October 5, 2023, BARDEHLE PAGENBERG requested – on behalf of their client 10x Genomics – the…

UPC News
IP News on
UPC News, Munich, Patent Litigation, Oppositions and Nullity, Chemistry, Pharma & Life Sciences
BARDEHLE PAGENBERG represents 10x Genomics in first UPC preliminary injunction hearing against NanoString

On September 5 and 6, the first preliminary injunction hearing before the Unified Patent Court,…

IP News on
Patent Prosecution, Chemistry, Pharma & Life Sciences, IP Reports
Regarding the patentability of plants and animals in Europe – the G 3/19 decision (“Pepper”) of the European Patent Office

European patents on plants, plant material or animals exclusively obtained by means of an…

Firm News on
Patent Prosecution, Trademarks, Chemistry, Pharma & Life Sciences
BARDEHLE PAGENBERG’s client LIVINGUARD AG launches a reusable face mask that inactivates SARS-CoV-2

Researchers at Freie Universität Berlin and RWTH Aachen have shown that the textiles used in face…

Firm News on
Patent Litigation, Oppositions and Nullity, Chemistry, Pharma & Life Sciences
BARDEHLE PAGENBERG navigates 10x Genomics to an extraordinary success against Bio-Rad Laboratories

The German Higher Regional Court of Munich decided that, in utility model infringement proceedings…